期刊文献+

心房颤动患者轻度认知功能障碍的研究进展 被引量:5

Research progress of mild cognitive impairment in patients with atrial fibrillation
下载PDF
导出
摘要 心房颤动可以通过炎症、低灌注、血栓栓塞等多重机制引起颅内病变并影响认知功能,增加轻度认知功能障碍(MCI)及痴呆的风险。MCI是认知功能下降过程中的早期阶段,是临床干预的关键时期,积极的多学科综合管理可延缓认知功能下降进程甚至一定程度改善认知功能,从而预防痴呆。心房颤动患者MCI的患病率居高不下,保护认知功能已逐渐成为心房颤动治疗领域的新话题。本文主要对心房颤动患者MCI的临床特征、相关危险因素及防治策略等进行综述。 Atrial fibrillation(AF)can cause intracranial pathological changes and increase the risk of the mild cognitive impairment(MCI)and dementia by multiple mechanism such as inflammation,low perfusion,thromboembolism.MCI is an early stage in the process of cognitive decline and is the key stage of clinical intervention.Active multidisciplinary managements can delay the decline of cognitive function and even improve cognitive function to a certain extent,so as to prevent dementia.The prevalence of MCI in patients with AF remains high,and the protection of cognitive function has gradually become a new topic in the field of AF treatment.This paper reviews the clinical features,related risk factors and prevention and treatment strategies of MCI in AF patients.
作者 王佳 赖一炜 戴雯莉 蒋超 Wang Jia;Lai Yiwei;Dai Wenli;Jiang Chao(Department of Cadre Medicine,Emergency General Hospital,Beijing 100028,China;Department of Cardiology,Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China)
出处 《中国医药》 2021年第1期138-141,共4页 China Medicine
关键词 心房颤动 轻度认知功能障碍 临床特征 Atrial fibrillation Mild cognitive impairment Clinical characteristics
  • 相关文献

参考文献5

二级参考文献35

  • 1[2]Gibbons RJJ,Antmrn EM,Alpert JS,et al. ACC/AHA /ESC guidelines for the management of patients with atrial fibrillation [J]. Eur Heart J, 2001,22: 1852 -1923
  • 2[3]Farshi R,Kistner D,Sarma JSM,et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a cross over open - label study of five drug regimens [ J ]. J Am Coll Cardiol,1999,33: 304 - 310
  • 3[5]Zoble RG, Brewington J, Olukotun AY, et al. Comparative effects of nadolol - digoxin combination therapy and digoxin monotherpy for chronic atrial fibrillation[J ]. Am J Cardiol, 1987,60: 39D- 45D
  • 4[6]Redfors A. Plasma digoxin concertration: its relation to digoxin dosage and clinical effects in patients with atrial fibrillation[ J ]. Br Heart J, 1972,34: 383 - 391
  • 5[7]Lang R, Klein HO, Weiss E, et al. Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation[ J ]. Chest, 1983,83:491 - 499
  • 6[8]Goldman S, Probst P, Selzer A, Cohn K. Inefficacy of "therapeutic serum levels of digoxin in controlling the ventricular rate in atrial fibrillation[J]. Am J Cardiol,1975,35:651 - 655
  • 7[9]Lewis RV. Irvine N, McDevitt DG. Relationship between heart rate,exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem [ J ]. Eur Heart J,1998,9: 777 - 781
  • 8[10]Ang EL. Chan WL, Cleland JGF. et al. Placebo controlled trial of xamoterol versus digoxin in chronic atrial fibrillation[J]. Br Heart J ,1990,64:256 - 260
  • 9[11]Sopher SM, Camm AJ. Atrial fibrillation; Maintenance of sinus rhythm versus rate control[J ]. Am J Cardiol,1996,77: 24A- 37A
  • 10[12]Segal JB. McNarmara RL, Miller MR et al. The evidence regarding the drugs used for ventricular rate control[J]. J Fam Pract, 2000,49: 47 - 59

共引文献38

同被引文献42

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部